Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-12-09 9:02 pm Unchanged | 2025-12-08 | 13G | Ovid Therapeutics Inc. OVID | Takeda Pharmaceutical Company Limited | 8,781,996 12.300% | 0 (Unchanged) | Filing History |
| 2025-12-08 11:45 am Purchase | 2025-11-28 | 13G | Ovid Therapeutics Inc. OVID | JANUS HENDERSON GROUP PLC JHG | 7,114,114 9.990% | 7,114,114 (New Position) | Filing History |
| 2025-07-21 6:36 pm Sale | 2025-07-17 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -3,853,818 (Position Closed) | Filing History |
| 2025-07-17 8:12 pm Sale | 2025-06-30 | 13G | Ovid Therapeutics Inc. OVID | BlackRock Inc. BLK | 1,369,010 1.900% | -2,950,908 (-68.31%) | Filing History |
| 2025-07-09 4:08 pm Sale | 2025-06-30 | 13G | Ovid Therapeutics Inc. OVID | Rubric Capital Management LP | 478,533 0.670% | -4,837,436 (-91.00%) | Filing History |
| 2025-02-14 5:41 pm Sale | 2024-12-31 | 13G | Ovid Therapeutics Inc. OVID | Madison Avenue Partners, LP | 2,852,352 4.000% | -796,157 (-21.82%) | Filing History |
| 2024-11-14 6:01 pm Sale | 2024-09-30 | 13G | Ovid Therapeutics Inc. OVID | EcoR1 Capital, LLC | 0 0.000% | -6,117,400 (Position Closed) | Filing History |
| 2024-11-14 4:39 pm Sale | 2024-09-30 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 3,853,818 5.400% | -2,997,233 (-43.75%) | Filing History |
| 2024-02-14 4:15 pm Sale | 2023-12-31 | 13G | Ovid Therapeutics Inc. OVID | LEVIN JEREMY M | 6,942,181 9.400% | -338,940 (-4.66%) | Filing History |
| 2024-02-14 11:10 am Purchase | 2023-12-31 | 13G | Ovid Therapeutics Inc. OVID | Madison Avenue Partners, LP | 3,648,509 5.200% | 39,455 (+1.09%) | Filing History |
| 2024-02-12 06:06 am Sale | 2023-12-31 | 13G | Ovid Therapeutics Inc. OVID | Rubric Capital Management LP | 5,315,969 7.520% | -1,512,096 (-22.15%) | Filing History |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Ovid Therapeutics Inc. OVID | BlackRock Inc. BLK | 4,319,918 6.100% | 3,117,188 (+259.18%) | Filing History |
| 2023-07-31 5:21 pm Purchase | 2023-07-20 | 13G | Ovid Therapeutics Inc. OVID | Madison Avenue Partners, LP | 3,609,054 5.100% | 3,609,054 (New Position) | Filing History |
| 2023-02-14 4:01 pm Purchase | 2022-12-31 | 13G | Ovid Therapeutics Inc. OVID | LEVIN JEREMY M | 7,281,121 10.000% | 726,351 (+11.08%) | Filing History |
| 2023-02-13 6:22 pm Purchase | 2022-12-31 | 13G | Ovid Therapeutics Inc. OVID | BIOTECHNOLOGY VALUE FUND L P | 6,851,051 9.700% | 220,000 (+3.32%) | Filing History |
| 2023-02-13 10:28 am Sale | 2022-12-31 | 13G | Ovid Therapeutics Inc. OVID | Stonepine Capital Management, LLC | 0 0.000% | -4,006,185 (Position Closed) | Filing History |
| 2023-02-10 4:00 pm Purchase | 2022-12-31 | 13G | Ovid Therapeutics Inc. OVID | Rubric Capital Management LP | 6,828,065 9.690% | 6,828,065 (New Position) | Filing History |
| 2023-02-10 2:28 pm Purchase | 2022-12-31 | 13G | Ovid Therapeutics Inc. OVID | EcoR1 Capital, LLC | 6,117,400 8.700% | 35,200 (+0.58%) | Filing History |
| 2023-02-09 11:30 am Sale | 2022-12-30 | 13G | Ovid Therapeutics Inc. OVID | The Vanguard Group | 2,581,736 3.660% | -860,882 (-25.01%) | Filing History |
| 2023-02-03 11:50 am Unchanged | 2022-06-21 | 13G | Ovid Therapeutics Inc. OVID | Takeda Pharmaceutical Company Limited | 0 0.000% | 0 (Unchanged) | Filing History |